Shots:

• Sorrento has entered into a research testing agreement with the UTMB for the preclinical testing of Sorrento’s therapeutic product candidates for COVID-19
• The preclinical testing will be performed in Dr. Paessler’s laboratory at UTMB which Sorrento called "one of only two maximum containment laboratories on a university campus in the US and one of just a few such BSL4 laboratories currently operating in the US
• Sorrento is currently conducting preclinical development of multiple candidates for COVID-19 across its platforms- including NK cell therapies- NAbs and COVIDTRAP to potentially inhibit the binding of SARS-CoV-2’s spike protein with ACE2 receptors- thereby preventing viral cell entry

Click here ­to­ read full press release/ article | Ref: Sorrento | Image: Sorrento